ProCE Banner Activity

PASO-DOBLE (GeSIDA 11720): Switch to DTG/3TC vs BIC/TAF/FTC in Virologically Suppressed Persons With HIV

Conference Coverage
Slideset

In open-label phase IV PASO-DOBLE (GeSIDA 11720), switch to DTG/3TC demonstrated noninferior efficacy and led to less weight gain than switch to BIC/TAF/FTC by Week 48.

Released: July 28, 2024

Expiration: July 27, 2025

Share

Faculty

Angela Davies

Angela Davies, MD

Assistant Professor of Medicine
UC Davis Cancer Center
Sacramento, CA

Amit “Mickey” Dhir

Amit “Mickey” Dhir, MBA, MSN, AGNP-C, AAHIVS

Infectious Disease Nurse Practitioner
Chase Brexton Health Care
Baltimore, Maryland

PT Faculty

Georgia Colangelo

Georgia Colangelo, RN, BSN, OCN

Collaborative Practice Nurse
Hillman Cancer Center
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare

Partners

IAS

ProCE Banner